Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Krystal Biotech Inc
4KBCurrent price
161.45 EUR
-4.99 EUR (-3.00%)
Last closed
177.39 USD
Company
www.krystalbio.com
ISIN
US5011471027
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
5 740 883 456 USD
Yield for 12 month
+63.92 %
1Y
3Y
5Y
10Y
15Y
4KB
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. Address: 2100 Wharton Street, Pittsburgh, PA, United States, 15203
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
207.78 USDP/E ratio
112.774Dividend Yield
–Current Year
+50 699 000 USD
Last Year
–
Current Quarter
+83 841 000 USD
Last Quarter
+70 284 000 USD
Current Year
+42 598 000 USD
Last Year
-4 054 999 USD
Current Quarter
+75 669 000 USD
Last Quarter
+62 289 000 USD
Key Figures 4KB
1 year
3 years
5 years
10 years
EBITDA
69 145 000 USD
Operating Margin TTM
PE Ratio
112.774
Return On Assets TTM
4.58 %
PEG Ratio
–
Return On Equity TTM
6.38 %
Wall Street Target Price
207.78 USD
Revenue TTM
241 519 008 USD
Book Value
30.81 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
879.9 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
1.77 USD
Diluted Eps TTM
1.77 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
-67.4 %
Profit Margin
21.68 %
Dividend Analytics 4KB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4KB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 4KB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
112.774
Forward PE
35.7143
Enterprise Value Revenue
21.3221
Price Sales TTM
23.7699
Enterprise Value EBITDA
28.4372
Price Book MRQ
6.469
Financials 4KB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 4KB
For 52 weeks
96.73 USD
219.34 USD
50 Day MA
181.29 USD
Shares Short Prior Month
3 523 481
200 Day MA
171.97 USD
Short Ratio
15.35
Shares Short
3 540 250
Short Percent
16.23 %
BeatStart